ATE323157T1 - Protease zum aktivierung des gerinnungsfaktor vii - Google Patents

Protease zum aktivierung des gerinnungsfaktor vii

Info

Publication number: ATE323157T1
Authority: AT; Austria
Prior art keywords: protease; kda; factor vii; clotting factor; heparin
Prior art date: 1998-04-24

Application number

AT99106913T

Other languages

English (en)

Inventor

Juergen Dr Roemisch

Hans-Arnold Stoehr

Annette Feussner

Original Assignee

Zlb Behring Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-24

Filing date

1999-04-08

Publication date

2006-04-15

1999-04-08 Application filed by Zlb Behring Gmbh filed Critical Zlb Behring Gmbh

2006-04-15 Application granted granted Critical

2006-04-15 Publication of ATE323157T1 publication Critical patent/ATE323157T1/de

Links

108091005804 Peptidases Proteins 0.000 title abstract 5
239000004365 Protease Substances 0.000 title abstract 5
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title abstract 5
239000003114 blood coagulation factor Substances 0.000 title abstract 3
229940012413 factor vii Drugs 0.000 title abstract 3
102000015081 Blood Coagulation Factors Human genes 0.000 title 1
108010039209 Blood Coagulation Factors Proteins 0.000 title 1
230000004913 activation Effects 0.000 title 1
108010054218 Factor VIII Proteins 0.000 abstract 2
102000001690 Factor VIII Human genes 0.000 abstract 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 2
230000003213 activating effect Effects 0.000 abstract 2
229960000301 factor viii Drugs 0.000 abstract 2
229960002897 heparin Drugs 0.000 abstract 2
229920000669 heparin Polymers 0.000 abstract 2
108010039627 Aprotinin Proteins 0.000 abstract 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 abstract 1
108010062466 Enzyme Precursors Proteins 0.000 abstract 1
102000010911 Enzyme Precursors Human genes 0.000 abstract 1
108010014172 Factor V Proteins 0.000 abstract 1
208000032843 Hemorrhage Diseases 0.000 abstract 1
229960004405 aprotinin Drugs 0.000 abstract 1
229910001424 calcium ion Inorganic materials 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
230000023597 hemostasis Effects 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
230000017854 proteolysis Effects 0.000 abstract 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 abstract 1
238000010186 staining Methods 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/38—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96447—Factor VII (3.4.21.21)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Hematology (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Pharmacology & Pharmacy (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Food Science & Technology (AREA)
Cell Biology (AREA)
Pathology (AREA)
Toxicology (AREA)
General Physics & Mathematics (AREA)
Materials Engineering (AREA)

AT99106913T 1998-04-24 1999-04-08 Protease zum aktivierung des gerinnungsfaktor vii ATE323157T1 (de)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
DE19818495		1998-04-24
DE19827734		1998-06-22
DE19851336		1998-11-06
DE19851332		1998-11-06
DE19851335		1998-11-06
DE19903693A DE19903693A1 (de)	1998-04-24	1999-02-01	Protease zur Aktivierung des Gerinnungsfaktors VII

Publications (1)

Publication Number	Publication Date
ATE323157T1 true ATE323157T1 (de)	2006-04-15

Family

ID=27545095

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99106913T ATE323157T1 (de)	1998-04-24	1999-04-08	Protease zum aktivierung des gerinnungsfaktor vii

Country Status (10)

Country	Link
US (4)	US6528299B1 (de)
EP (1)	EP0952215B1 (de)
JP (2)	JP4361986B2 (de)
KR (2)	KR100776921B1 (de)
AT (1)	ATE323157T1 (de)
AU (1)	AU748221B2 (de)
CA (1)	CA2269109C (de)
DE (2)	DE19903693A1 (de)
DK (1)	DK0952215T3 (de)
ES (1)	ES2262264T3 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19903693A1 (de) *	1998-04-24	1999-10-28	Centeon Pharma Gmbh	Protease zur Aktivierung des Gerinnungsfaktors VII
DE19937219A1 (de) *	1999-08-06	2001-02-08	Aventis Behring Gmbh	Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie
EP1023902A1 (de)	1999-01-28	2000-08-02	Aventis Behring Gesellschaft mit beschränkter Haftung	Pharmazeitische Zubereitungent zür Behandlung von zündlichen Prozessen
DE10023923A1 (de)	1999-06-10	2000-12-14	Aventis Behring Gmbh	Verfahren zur Bestimmung der Aktivität der Faktor VII-aktivierenden Protease aus Proteinlösungen
DE19937218A1 (de)	1999-08-06	2001-02-08	Aventis Behring Gmbh	Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie
DE50115042D1 (de) *	2000-07-26	2009-09-24	Csl Behring Gmbh	Mutanten der den Faktor VII aktivierenden Protease und Nachweisverfahren mit spezifischen Antikörpern
US7153679B2 (en)	2000-07-26	2006-12-26	Aventis Behring Gmbh	Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis
DE10036641A1 (de) *	2000-07-26	2002-02-14	Aventis Behring Gmbh	Monoklonale Antikörper für die den Blutgerinnungsfaktor VII aktivierende Protease (FSAP)und ihre Verwendung
DE10238429A1 (de)	2002-03-19	2003-10-30	Aventis Behring Gmbh Intellect	Marburg I Mutante der Faktor VII aktivierenden Protease (FSAP) als Risikofaktor für Atherosklerose
DE50114021D1 (de)	2001-01-08	2008-07-24	Csl Behring Gmbh	Stabilisierte Flüssigzubereitung der den Blutgerinnungsfaktor VII aktivierenden Protease oder ihres Proenzyms
ES2391802T3 (es) *	2001-01-31	2012-11-30	Asahi Kasei Pharma Corporation	Composición para el ensayo de proteínas glicosiladas
DE10148037A1 (de) *	2001-09-28	2003-04-17	Aventis Behring Gmbh	Verwendung der den Blutgerinnungsfaktor VII aktivierenden Protease zur Prophylaxe und Therapie von vaso-proliferativen Erkrankungen
JP2005530683A (ja)	2001-12-21	2005-10-13	ノボノルディスクヘルスケアアクチェンゲゼルシャフト	第ｖｉｉ因子ポリペプチドの液体組成物
DE10205520A1 (de) *	2002-02-08	2003-08-14	Aventis Behring Gmbh	Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease
CN101912601B (zh)	2002-06-21	2012-08-29	诺和诺德医疗保健公司	因子vii多肽的稳定化固体组合物
DE10309368A1 (de) *	2002-08-06	2004-02-26	Aventis Behring Gmbh Intellectual Property/Legal	Pharmazeutische Zubereitung mit RNA als Cofaktor der Hämostase
JP3830501B2 (ja) *	2003-01-17	2006-10-04	株式会社ティーティーシー	アフィニティートラップリアクター、及びそれを用いたアンジオスタチン様断片のヒト血漿からの一段階精製プロセス
US7897734B2 (en)	2003-03-26	2011-03-01	Novo Nordisk Healthcare Ag	Method for the production of proteins
KR20060015574A (ko)	2003-05-23	2006-02-17	노보 노르디스크 헬스 케어 악티엔게젤샤프트	용액 중 단백질 안정화
EP1495766A1 (de) *	2003-07-10	2005-01-12	ZLB Behring GmbH	Blutgerinnungsfaktor VII aktivierenden Protease (FSAP) Derivate zur Behandlung von angiogenesebezogenen Krankheiten
EP1656158B1 (de)	2003-08-14	2016-03-09	Novo Nordisk Health Care AG	Flüssige, wässrige pharmazeutische zusammensetzung von faktor-vii-polypeptiden
DE10346751A1 (de) *	2003-10-06	2005-04-21	Transmit Technologietransfer	Clot-Lysis-Assay
EP2311437A1 (de)	2003-12-19	2011-04-20	Novo Nordisk Health Care AG	Stabilisierte Zusammensetzungen von Faktor-VII-Polypeptiden
DE102005026163A1 (de)	2004-08-24	2006-03-02	Dade Behring Marburg Gmbh	Gegen den Marburg I Polymorphismus der Faktor VII aktivierenden Protease (FSAP) gerichtete Antikörper, ihre Herstellung und Verwendung
DK1801233T3 (da)	2005-12-22	2010-02-08	Siemens Healthcare Diagnostics	Diagnostisk fremgangsmåde til genkendelse af bærere af Marburg I-varianten af den faktor VII-aktiverende protease (FSAP) ved differentiel modulering af FSAP-aktiviteten
US20100172830A1 (en) *	2007-03-29	2010-07-08	Cellx Inc.	Extraembryonic Tissue cells and method of use thereof
US8545459B2 (en) *	2009-02-25	2013-10-01	Teleflex Medical Incorporated	Stabilized enzyme compositions
US9333280B2 (en)	2009-02-25	2016-05-10	Teleflex Medical Incorporated	Stabilized enzyme compositions
EP2386652A1 (de)	2010-05-12	2011-11-16	Siemens Healthcare Diagnostics Products GmbH	Homogenes Verfahren zur Bestimmung der Plasminogenaktivator-aktivierenden Aktivität der FSAP
WO2014135694A1 (en)	2013-03-08	2014-09-12	Csl Behring Ag	Treatment and prevention of remote ischemia-reperfusion injury
CA2916399C (en) *	2013-06-28	2022-08-02	Marc Nolte	Combination therapy using a factor xii inhibitor and a c1-inhibitor
US10143413B2 (en)	2014-06-13	2018-12-04	Kurin, Inc.	Catheter insertion device with blood analyzer
US10010282B2 (en)	2015-07-24	2018-07-03	Kurin, Inc.	Blood sample optimization system and blood contaminant sequestration device and method
US10827964B2 (en)	2017-02-10	2020-11-10	Kurin, Inc.	Blood contaminant sequestration device with one-way air valve and air-permeable blood barrier with closure mechanism
IL286812B2 (en)	2019-04-01	2025-12-01	Kurin Inc	Non-venting bodily fluid sample optimization device and system
CN118464887A (zh) *	2024-07-09	2024-08-09	山东省食品药品检验研究院	一种用于肝素效价测定的终止液及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4363319A (en) *	1980-06-30	1982-12-14	Applied Medical Devices, Inc.	Ready-to-use bandage incorporating a coagulant composition and method of preparing same
FR2504921A1 (fr) *	1981-04-30	1982-11-05	Choay Sa	Medicament nouveau constitue par un complexe aprotinine-plasmine et procede de preparation de ce nouveau complexe
US4447412A (en) *	1983-02-01	1984-05-08	Bilton Gerald L	Enzyme-containing digestive aid compostions
US5175087A (en) *	1987-07-06	1992-12-29	Biopool International, Inc.	Method of performing tissue plasminogen activator assay
US5703055A (en) *	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
EP0482088B1 (de) *	1989-07-20	1999-03-31	Analytical Control Systems, Inc.	Verbesserte kontrollverfahren für stabile blutkoagulation
AU2793292A (en) *	1991-10-11	1993-05-03	Novo Nordisk A/S	Hemostatic composition for local hemostasis
AU3479495A (en) *	1994-09-30	1996-04-26	Ppl Therapeutics (Scotland) Ltd	Alpha-1-antitrypsin and antithrombine-iii variants
US6359054B1 (en) *	1994-11-18	2002-03-19	Supratek Pharma Inc.	Polynucleotide compositions for intramuscular administration
DE19903693A1 (de) *	1998-04-24	1999-10-28	Centeon Pharma Gmbh	Protease zur Aktivierung des Gerinnungsfaktors VII
DE19937219A1 (de) *	1999-08-06	2001-02-08	Aventis Behring Gmbh	Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie
DE10023923A1 (de) *	1999-06-10	2000-12-14	Aventis Behring Gmbh	Verfahren zur Bestimmung der Aktivität der Faktor VII-aktivierenden Protease aus Proteinlösungen
DE19937218A1 (de) *	1999-08-06	2001-02-08	Aventis Behring Gmbh	Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie
US7153679B2 (en) *	2000-07-26	2006-12-26	Aventis Behring Gmbh	Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis
DE50115042D1 (de) *	2000-07-26	2009-09-24	Csl Behring Gmbh	Mutanten der den Faktor VII aktivierenden Protease und Nachweisverfahren mit spezifischen Antikörpern
DE50114021D1 (de) *	2001-01-08	2008-07-24	Csl Behring Gmbh	Stabilisierte Flüssigzubereitung der den Blutgerinnungsfaktor VII aktivierenden Protease oder ihres Proenzyms
DE10148037A1 (de) *	2001-09-28	2003-04-17	Aventis Behring Gmbh	Verwendung der den Blutgerinnungsfaktor VII aktivierenden Protease zur Prophylaxe und Therapie von vaso-proliferativen Erkrankungen
DE10205520A1 (de) *	2002-02-08	2003-08-14	Aventis Behring Gmbh	Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease

1999
- 1999-02-01 DE DE19903693A patent/DE19903693A1/de not_active Withdrawn
- 1999-04-08 DK DK99106913T patent/DK0952215T3/da active
- 1999-04-08 ES ES99106913T patent/ES2262264T3/es not_active Expired - Lifetime
- 1999-04-08 DE DE69930778T patent/DE69930778T2/de not_active Expired - Lifetime
- 1999-04-08 EP EP99106913A patent/EP0952215B1/de not_active Expired - Lifetime
- 1999-04-08 AT AT99106913T patent/ATE323157T1/de active
- 1999-04-21 US US09/295,316 patent/US6528299B1/en not_active Expired - Lifetime
- 1999-04-23 AU AU23935/99A patent/AU748221B2/en not_active Ceased
- 1999-04-23 CA CA2269109A patent/CA2269109C/en not_active Expired - Lifetime
- 1999-04-23 KR KR1019990014636A patent/KR100776921B1/ko not_active Expired - Fee Related
- 1999-04-23 JP JP11641199A patent/JP4361986B2/ja not_active Expired - Fee Related
2002
- 2002-12-16 US US10/319,592 patent/US6911334B2/en not_active Expired - Lifetime
2005
- 2005-05-02 US US11/118,396 patent/US20050202002A1/en not_active Abandoned
2006
- 2006-09-29 KR KR1020060096156A patent/KR20060107736A/ko not_active Ceased
2007
- 2007-11-13 US US11/984,058 patent/US7879803B2/en not_active Expired - Fee Related
2009
- 2009-03-11 JP JP2009057232A patent/JP4422781B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69930778T2 (de)	2007-03-29
US20030152567A1 (en)	2003-08-14
KR100776921B1 (ko)	2007-11-20
DE19903693A1 (de)	1999-10-28
US6911334B2 (en)	2005-06-28
DK0952215T3 (da)	2006-08-07
JP4422781B2 (ja)	2010-02-24
AU2393599A (en)	1999-11-04
EP0952215A2 (de)	1999-10-27
US7879803B2 (en)	2011-02-01
US20050202002A1 (en)	2005-09-15
AU748221B2 (en)	2002-05-30
JP2009131273A (ja)	2009-06-18
EP0952215A3 (de)	2002-06-26
US20080175878A1 (en)	2008-07-24
KR20060107736A (ko)	2006-10-16
US6528299B1 (en)	2003-03-04
JP4361986B2 (ja)	2009-11-11
DE69930778D1 (de)	2006-05-24
EP0952215B1 (de)	2006-04-12
JP2000023696A (ja)	2000-01-25
CA2269109C (en)	2010-06-15
CA2269109A1 (en)	1999-10-24
KR19990083444A (ko)	1999-11-25
ES2262264T3 (es)	2006-11-16

Legal Events

Date

Code

Title

Description

2007-02-15

UEP

Publication of translation of european patent specification

Ref document number: 0952215

Country of ref document: EP

2007-11-15

EEFA

Change of the company name

Publication	Publication Date	Title
DE69930778D1 (de)	2006-05-24	Protease zum Aktivierung des Gerinnungsfaktor VII
CA2155931A1 (en)	1994-08-18	Inhibitors of thrombosis
MX9606386A (es)	1997-03-29	Agentes que afectan la hemostasis trombotica.
IL128079A0 (en)	1999-11-30	Thiol sulfone metalloprotease inhibitors
KR970064594A (ko)	1997-10-13	노화방지용 화장품 조성물
ZA959819B (en)	1996-05-30	Substituted heterocylic compounds useful as inhibitors of (serine protease) human neutrophil elastase
MY122696A (en)	2006-04-29	Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases.
WO1996035788A3 (en)	1996-12-12	Kunitz type protease inhibitors
DE69823935D1 (de)	2004-06-24	Aus dem Epidermis isolierte Polypeptide und Verwendung davon
AU639257B2 (en)	1993-07-22	Proteins having anticoagulant properties
ATE318606T1 (de)	2006-03-15	Zusammenstellungen zur prophylaxe und behandlung von allergien des typus i
DE3587526D1 (de)	1993-09-16	Serinproteaseinhibitoren und isolierungsverfahren dazu.
WO1999063090A3 (en)	2000-03-02	Protease inhibitor peptides
EP1497326A4 (de)	2005-12-21	Prothrombin aktivierendes protein
PT1268463E (pt)	2005-05-31	4-pironas substituidas com arilo e heteroarilo policiclicos uteis para a inibicao selectiva da cascata de coagulacao
WO1999002565A3 (de)	1999-04-22	Mittel zur behandlung und/oder prophylaxe von mikrozirkulationsstörungen
IL80230A0 (en)	1987-01-30	Protein binding agent
HK1043534A1 (zh)	2002-09-20	蛋白酶抑制剂
WO2003053999A3 (de)	2003-11-06	Selektive arylguanidinpeptide als urokinaseinhibitoren
AU2003200420B2 (en)	2010-01-28	Inhibitory, Monoclonal antibody against blood clotting factor VII-activating protease
WO2001079155A3 (en)	2002-05-16	Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
ATE353666T1 (de)	2007-03-15	Verwendung von aktiviertem gerinnungsfaktor vii zur behandlung von durch thrombolytische therapie-induzierten wichtigen blutungen
WO2002053172A3 (en)	2004-02-26	Use of matrix metalloproteinase peptide substrate to lower the rate of extracellular matrix turnover
WO2002038122A3 (fr)	2002-08-08	Compositions exemptes de protease, comprenant une glycosidase
SE9904059D0 (sv)	1999-11-10	Serine protease and topical retinoid compositions